Founded in Wilmington, Delaware, OrphageniX is a biopharmaceutical company launched in 2007 to commercialize the Company’s dominant IP portfolio covering targeted gene alteration (TGA). OrphageniX owns the worldwide exclusive license for gene editing using single stranded oligonucleotides invented by University of Delaware researcher Dr. Eric Kmiec. The Company has assembled an experienced management team, created strategic plans for therapeutic development and selected target areas of critical unmet need.
